Do You Need A COVID-19 Booster Dose? Pfizer-BioNTech Submit Initial Data To Support Idea

Pfizer Inc PFE and BioNTech SE BNTX have submitted Phase 1 data to the FDA to support the evaluation of their COVID-19 booster dose for future licensure.
The data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks.
Phase 1 data, part of the companies' Phase 1/2/3 trial program, evaluated a third dose's safety, tolerability, and immunogenicity from the Phase 1 trial of the two-dose series.
Related content: Do mRNA COVID-19 Vaccines Cause Skin Or Kidney Disorders?
Participants received a 30-µg booster dose 8 to 9 months after receiving the second dose. Results from the group showed that the third dose elicited significantly higher neutralizing antibodies against the initial virus and variants.
Phase 3 results evaluating the third dose are expected shortly.
Last week, FDA authorized a third mRNA COVID-19 vaccine booster shot to immunocompromised individuals. The CDC panel also voted in favor of the recommendation.
Price Action: PFE shares are up 0.98% at $48.96, while BNTX stock dropped 9.21% at $342.94 during the market session on the last check Monday.
Photo by x3 from Pixabay